Autopsy report · NCT00470535

Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

“This study was terminated earlier due to a phase III study that showed this drug inferior to sorafenib”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 3 years 8 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 4 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Roswell Park Cancer Institute

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

erlotinib hydrochloride; immunohistochemistry staining method; laboratory biomarker analysis

Participants

18

Sites

1

Countries

United States

Trials that died the same way

• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
  “The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been approved).The sponsor terminated the trial.” (71% match in meaning)
• A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
  “This study was terminated due to limited efficacy and not due to safety reasons” (63% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (63% match in meaning)
• A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
  “Phase III study results for the drug Tesquinimod were not promising so it was a drug development decision to stop using the drug” (61% match in meaning)
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
  “The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.